TITLE

TRANSITION TO BEGIN ISLET NEOGENESIS U.K. PHASE I TRIAL

PUB. DATE
November 2002
SOURCE
Worldwide Biotech;Nov2002, Vol. 14 Issue 11, p2
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports the approval received by Transition Therapeutics Inc. to conduct the first phase of trials of its islet neogenesis therapy in Great Britain.
ACCESSION #
7692333

 

Related Articles

  • Clinic Roundup.  // BioWorld Today;9/20/2010, Vol. 21 Issue 181, p4 

    This section offers news briefs on clinical trials, including the clinical results for Emisphere Technologies Inc.'s oral drug delivery technology in an appetite suppression study, and Transition Therapeutics Inc.'s decision to stop development of TT-223 after a study in diabetes patients missed...

  • Transition Therapeutics completes enrollment for trial of interferon enhancing therapy.  // PharmaWatch: CNS;July 2003, Vol. 2 Issue 7, p19 

    Reports on the completion of the clinical trial of the interferon enhancer EMZ701 conducted by Transition Therapeutics Inc. in the U.S. Assessment on the side effects of the drugs; Use of the drugs during the treatment of the patients with multiple sclerosis; Availability of the products.

  • Alzheimer's Disease Update.  // PharmaWatch: CNS;Jun2006, Vol. 5 Issue 6, p7 

    The article reports on developments in the treatment of Alzheimer's disease as of June 2006. A phase I clinical trial has been planned by Eisai for its E2012 gamma secretase modulator. Prana Biotechnology will advance its proprietary lead compound PBT2 with a phase IIa clinical trial. Health...

  • CNS News Round-Up.  // PharmaWatch: CNS;Oct2007, Vol. 6 Issue 10, p2 

    The article offers news briefs related to pharmaceuticals in the U.S. Neurochem Inc. reported disappointing results from its Phase III clinical trial designed to assess the safety, efficacy and disease modification effect of Alzhamed. Transition Therapeutics Inc. stated that its experimental...

  • Alzheimer's Disease Update.  // PharmaWatch: CNS;Oct2007, Vol. 6 Issue 10, p5 

    The article offers news briefs related to Alzheimer's disease drug trial in the U.S. Neurochem Inc. has reported disappointing top-line results from its Phase III clinical trial designed to assess the safety, efficacy and disease modification effect of Alzhamed for the treatment of Alzheimer's...

  • CNS News Round-Up.  // PharmaWatch: Monthly Review;Oct2007, Vol. 6 Issue 10, p14 

    The article offers news briefs related to the pharmaceutical industry. Neurochem Inc. has reported disappointing results from its Phase III clinical trial aimed to assess the safety, efficacy and disease modification effect of Alzhamed, a drug for Alzheimer's disease. Transition Therapeutics...

  • Multiple Sclerosis News Headlines May 15, 2003 - June 14, 2003.  // PharmaWatch: CNS;July 2003, Vol. 2 Issue 7, p19 

    Reports developments on issues related to the treatment of multiple sclerosis as of July 2003. Details on the results of the first phase of the clinical trial of an interferon enhancing therapy conducted by Transition Therapeutics Inc.; Assessment on the efficacy of the Rebif drugs on patients...

  • Transition Therapeutics: showing potential in hepatitis.  // PharmaWatch: Monthly Review;Sep2006, Vol. 5 Issue 9, p33 

    The article reports that Toronto-based Transition Therapeutics Inc. has posted positive 12-week data from a phase I/II trial investigating the safety and efficacy of HCV-IET in hepatitis C non-responders. HCV-IET combines Transition's interferon enhancer EMZ702 with the current standard of care...

  • CLINIC ROUNDUP.  // BioWorld Today;12/27/2007, Vol. 18 Issue 249, p3 

    This section provides updates on clinical trials in the biotechnology industry as of December 27, 2007. AVI BioPharma Inc. dosed the first patient in a proof-of-concept trial of AVI-4658 in Duchennes muscular dystrophy. Sinovac Biotech Ltd. reported positive top-line results from its Phase II...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics